Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies

PURPOSE: Fruquintinib is an anti-vascular endothelial growth factor receptor (VEGFR) agent. The FRESCO trial demonstrated that patients with metastatic colorectal cancer (mCRC) refractory to standard therapies could benefit from fruquintinib with tolerable adverse events (AEs). However, the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Cao, Huijiao, Jiang, Chang, He, Wenzhuo, You, Yafei, Peng, Kunwei, Jin, Yanan, Xia, Liangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691567/
https://www.ncbi.nlm.nih.gov/pubmed/33282739
http://dx.doi.org/10.3389/fonc.2020.587692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691567/
https://www.ncbi.nlm.nih.gov/pubmed/33282739
http://dx.doi.org/10.3389/fonc.2020.587692

Ejemplares similares